USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/11289
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZarura, Shafea-
dc.date.accessioned2020-07-13T12:58:07Z-
dc.date.available2020-07-13T12:58:07Z-
dc.date.issued2018-
dc.identifier.citationZARURA, Shafea. Contemporary management of obesity. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 279.en_US
dc.identifier.urihttps://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/11289-
dc.descriptionDepartment of Pharmacology and Clinical Pharmacy, Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldovaen_US
dc.description.abstractIntroduction. Obesity has become a serious public health problem in most industrialized countries, affecting a growing segment of the population. Aim of the study. Study of etiopathogenetic factors, consequences and strategies of obesity treatment in Moldova and Israel. Materials and methods. 220 patients overweight were evaluated in 2017 aged 40-79. I used the questionnaire to investigate clinical cases. Results. Our group is made up of 30% male subjects and the vast majority of 70% of female subjects. 76% of the subjects in the control group claim 3-5 meals per day, 13% consume 2-3 meals / day and only 14% - between 5-7 meals / dayIt is noticed that 55% of patients have a sedentary activity at work 40% of people were diagnosed but dyslipidemia, 20% with diabetes, 15% with hypertension, and 25% with associated diseases. It was found that 37% of patients were treated with Orlistat and 19% with Lorcaserin, of which 49% of patients treated with Orlistat and 40% of patients treated with Lorcaserin lost ≥ 10% of baseline body weight after 6 months of treatment, the mean weight difference between these preparations being 3.2 kg. Conclusions. Obesity is associated with numerous complications, such as dyslipidemia, diabetes, hypertension, etc. After 6 months of treatment, the mean difference in weight loss of Orlistat and Lorcaserin was 3.2 kg.en_US
dc.language.isoenen_US
dc.publisherMedEsperaen_US
dc.subjectobesityen_US
dc.subjectOrlistaten_US
dc.subjectLorcaserinaen_US
dc.titleContemporary management of obesityen_US
dc.typeArticleen_US
Appears in Collections:MedEspera 2018

Files in This Item:
File Description SizeFormat 
Zarura_Shafea.pdf500.14 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback